000908 Hunan Jingfeng Pharmaceutical
- 1.80
- -0.09-4.76%
Hunan Jingfeng Pharmaceutical News
Jingfeng Pharmaceutical (000908.SZ) announced first-quarter results, net profit of 3.553 million yuan, an increase of 174.14%
Jingfeng Pharmaceutical (000908.SZ) released its report for the first quarter of 2024. The company's revenue was 1.01...
Hunan Jingfeng Pharmaceutical Co.,Ltd. (SZSE:000908) Looks Inexpensive After Falling 38% But Perhaps Not Attractive Enough
The Hunan Jingfeng Pharmaceutical Co.,Ltd. (SZSE:000908) share price has fared very poorly over the last month, falling by a substantial 38%. Instead of being rewarded, shareholders who have alread
Jingfeng Pharmaceutical (000908.SZ): The company's stock may be subject to a delisting risk warning
Zhitong Finance App News, Jingfeng Pharmaceutical (000908.SZ) issued an announcement. According to preliminary estimates by the company's finance department, the company's net assets are expected to be negative at the end of 2023. If the company's net assets at the end of the 2023 audited period are negative, according to the relevant provisions of the “Shenzhen Stock Exchange Stock Listing Rules”, the company's stock transactions will be subject to a delisting risk warning after disclosing the 2023 annual report.
Jingfeng Pharmaceutical (000069.SZ): The company's stock may be subject to a delisting risk warning
Jingfeng Pharmaceutical (000069.SZ) issued an announcement. According to preliminary estimates by the company's finance department, the company expects 2023...
Even After Rising 19% This Past Week, Hunan Jingfeng PharmaceuticalLtd (SZSE:000908) Shareholders Are Still Down 49% Over the Past Five Years
This month, we saw the Hunan Jingfeng Pharmaceutical Co.,Ltd. (SZSE:000908) up an impressive 84%. But if you look at the last five years the returns have not been good. You would have done a lot b
Lacklustre Performance Is Driving Hunan Jingfeng Pharmaceutical Co.,Ltd.'s (SZSE:000908) 29% Price Drop
The Hunan Jingfeng Pharmaceutical Co.,Ltd. (SZSE:000908) share price has fared very poorly over the last month, falling by a substantial 29%. Instead of being rewarded, shareholders who have alread
Jingfeng Pharmaceutical (000908.SZ): Expected net loss of 190 million yuan to 230 million yuan in 2023
Gelonghui, January 29丨Jingfeng Pharmaceutical (000908.SZ) announced that it expects a net loss of 190 million yuan to 230 million yuan in 2023, deducting non-net loss of 190 million yuan to 240 million yuan, and operating income of 650 million yuan to 80 million yuan. The main reasons for the changes in the company's performance in 2023:1. The company's important product, Shenxiao Glucose Injection, withdrew from the medical insurance catalogue, and product sales dropped sharply compared to the same period last year; 2. Sales volume of the company's important product, sodium hyaluronate injection, fell short of expectations; 3. Dalian Deze Pharmaceutical Co., Ltd., an important subsidiary of the company, due to the operating period
Jingfeng Pharmaceutical (000908.SZ): The holding subsidiary has been applied for liquidation
Gelonghui November 24 | Jingfeng Pharmaceutical (000908.SZ) announced that Dalian Deze Pharmaceutical Co., Ltd., a holding subsidiary of Shanghai Jingfeng Pharmaceutical Co., Ltd., a wholly-owned subsidiary of Shanghai Jingfeng Pharmaceutical Co., Ltd., recently received a “Civil Ruling” from the Dalian Intermediate People's Court, ruling to revoke the civil ruling of the People's Court of Jinzhou District of Dalian City. The case was handled by the People's Court of Jinzhou District of Dalian City. Shanghai Jingfeng Pharmaceutical Co., Ltd. has objections to the above ruling of the Dalian Intermediate People's Court in Liaoning Province and has appointed lawyers to defend its rights in accordance with the law. There is uncertainty about whether Dalian Deze Pharmaceutical Co., Ltd. will eventually be forcibly liquidated. The company will pay close attention to the matter after
Jingfeng Pharmaceutical (000908.SZ): Products are mainly distributed in cardiovascular and cerebrovascular fields, oncology fields, and orthopedics
On November 20, Gelonghui, Jingfeng Pharmaceutical (000908.SZ) stated on the investor interactive platform that the company's products are mainly distributed in the cardiovascular and cerebrovascular fields, oncology, and orthopedics.
Jingfeng Pharmaceutical (000908.SZ): Creditors apply to court for pre-restructuring of the company
Jingfeng Pharmaceutical (000908.SZ) issued a notice. The company recently received “...” from the People's Court of Longkou City, Shandong Province
Hunan Jingfeng PharmaceuticalLtd (SZSE:000908 Investor Three-year Losses Grow to 46% as the Stock Sheds CN¥370m This Past Week
While not a mind-blowing move, it is good to see that the Hunan Jingfeng Pharmaceutical Co.,Ltd. (SZSE:000908) share price has gained 11% in the last three months. But that doesn't change the fact
Interpretation of Jingfeng Pharmaceutical's 2023 Interim Report: Operating pressure is evident, product investment in R&D is huge, and sales season has not yet reached
The 2023 interim report of Jingfeng Pharmaceutical (stock code: 000908) has been published. This article will thoroughly interpret its business situation from the perspective of financial data. First, we note that Jingfeng Pharmaceutical's revenue for the first half of 2023 was 380,521,926.69 yuan, down 5.34% from 402,009,285.92 yuan in the same period last year. This is mainly due to the withdrawal of Shenxiong Glucose Injection from medical insurance and the decline in sales volume. Meanwhile, net profit attributable to shareholders of listed companies was -12,845,641.09 yuan, compared with -11,462 in the same period last year.
Jingfeng Pharmaceutical (000908.SZ) released the first half of the year results, with a net loss of 12845,600 yuan
Jingfeng Pharmaceutical (000908.SZ) released the 2023 semi-annual report. During the reporting period, the company achieved operating income...
What Hunan Jingfeng Pharmaceutical Co.,Ltd.'s (SZSE:000908) 26% Share Price Gain Is Not Telling You
Hunan Jingfeng Pharmaceutical Co.,Ltd. (SZSE:000908) shareholders would be excited to see that the share price has had a great month, posting a 26% gain and recovering from prior weakness. While re
Hunan Jingfeng PharmaceuticalLtd (SZSE:000908 Investor Five-year Losses Grow to 47% as the Stock Sheds CN¥484m This Past Week
The main aim of stock picking is to find the market-beating stocks. But even the best stock picker will only win with some selections. At this point some shareholders may be questioning their invest
Hunan Jingfeng Pharmaceutical Co.,Ltd.'s (SZSE:000908) Largest Shareholders Are Individual Investors Who Were Rewarded as Market Cap Surged CN¥387m Last Week
If you want to know who really controls Hunan Jingfeng Pharmaceutical Co.,Ltd. (SZSE:000908), then you'll have to look at the makeup of its share registry. The group holding the most number of shares
Is Hunan Jingfeng PharmaceuticalLtd (SZSE:000908) A Risky Investment?
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the permanent loss of capital.' It's only natural to consider a company's balance sheet w
Review of December 24: full momentum this week, release the volume of the main funds to attack 5 shares next week.
December 24 news, the three major indices opened low, and then Prev maintained a low consolidation, the gem index led two cities down. In terms of the plate, medicine-related plates collectively rose, Chinese medicine stocks led the rise, food processing, retail and other consumer stocks were active against the trend; lithium batteries, photovoltaic, energy storage and other new energy tracks fell across the board, of which the weight fell more than 9% in the Ningde era. The index continued to weaken in the afternoon, with the gem index falling 2.7% at one point. Cultivate diamond, NFT concept stocks pull up; automobile, rare earth, fluorine chemical industry, digital currency and other sectors in the doldrums. Overall, market sentiment cooled, individual stocks showed a general downward trend, the two markets
Analysis of the limit of Jingfeng Medicine on December 24: traditional Chinese Medicine, Heparin, concept Hot stocks of assisted Reproduction
Jingfeng Pharmaceutical rose and closed with a closing price of 4.3 yuan. The stock rose by the daily limit at 10:15, but did not open the limit. The closing fund was 38.6444 million yuan, accounting for 1.19% of its current market value. In terms of capital flow data, the net inflow of main funds on the same day was 104 million yuan, the net inflow of hot capital was 96.7568 million yuan, and the net outflow of retail funds was 62.5951 million yuan. The flow of funds in the past five days is shown in the following table: this unit is a hot stock of traditional Chinese medicine, heparin and assisted reproduction concept. On the same day, the concept of traditional Chinese medicine rose 4.04%, the concept of heparin rose 2.83%, and the concept of assisted reproduction rose 1.64%. The evidence of this article
A-share change | Registration approval for the trading limit of Jingfeng Pharmaceutical (000908.SZ)
On December 24, Gelonghui Jingfeng Pharmaceutical (000908.SZ) rose by the daily limit of 4.30 yuan, with a total market value of 3.78 billion, a turnover rate of 6%, and now has more than 200000 orders. Beijing Pudkangli Pharmaceutical Science and Technology Development Co., Ltd., a subsidiary, was approved by the State Drug Administration for the registration of the chemical flurbiprofen axetil injection, the company announced yesterday. The approval of this product will help to optimize the company's product structure and improve market competitiveness, and this approval will not have a significant impact on the company's near-term performance.
Analysis
Price Target
No Data
